Witryna28 maj 2024 · We report the primary disease-free survival (DFS) results from the pre-planned interim analysis of IMpower010, a randomized phase 3 open-label trial of adjuvant atezolizumab (atezo; anti–PD-L1) vs best supportive care (BSC) after adjuvant chemo in patients (pts) with early-stage resected NSCLC. Witryna24 cze 2024 · The CASPIAN trial assessed durvalumab in combination with ... Furthermore, in the Impower 132 trial , a randomized, phase III study (investigating atezolizumab plus carboplatin or cisplatin and pemetrexed vs. carboplatin or cisplatin and pemetrexed), 4 of 291 patients (1.37%) developed encephalitis or meningitis. In the …
A Study of Atezolizumab in Combination With Carboplatin or …
Witrynaesmo.org IMpower130: efficacy and safety from a randomised phase 3 study of carboplatin and nab-paclitaxel with or without atezolizumab in 1L advanced non-squamous NSCLC Witryna9 lut 2024 · IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients Makoto Nishio,1 Haruhiro … firstscreenteam
Atezolizumab in combination with carboplatin plus nab ... - PubMed
Witryna20 wrz 2024 · The trial had 91% power for the primary analysis of disease-free survival in all patients in the stage II–IIIA population, with an HR for disease recurrence or death of 0·73 (corresponding to median disease-free survival durations of 46·6 months in the atezolizumab group and 34 months in the best supportive care group). Witryna30 maj 2024 · A global, Phase III, randomized, open-label trial, IMpower132 (NCT02657434), is being conducted to evaluate 1L atezo + platinum-based chemo + … Witryna20 lut 2015 · This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with … first screen tarzan lincoln crossword